Abstract:Background-Drug-induced arrhythmia is one of the most common causes of drug development failure and withdrawal from market. This study tested whether human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) combined with a low-impedance microelectrode array (MEA) system could improve on industry-standard preclinical cardiotoxicity screening methods, identify the effects of well-characterized drugs, and elucidate underlying risk factors for drug-induced arrhythmia. hiPSC-CMs may be advantageous over immortalized cell lines because they possess similar functional characteristics as primary human cardiomyocytes and can be generated in unlimited quantities.Methods and Results-Pharmacological responses of beating embryoid bodies exposed to a comprehensive panel of drugs at 65 to 95 days postinduction were determined. Responses of hiPSC-CMs to drugs were qualitatively and quantitatively consistent with the reported drug effects in literature. Torsadogenic hERG blockers, such as sotalol and quinidine, produced statistically and physiologically significant effects, consistent with patch-clamp studies, on human embryonic stem cell-derived cardiomyocytes hESC-CMs. False-negative and false-positive hERG blockers were identified accurately. Consistent with published studies using animal models, early afterdepolarizations and ectopic beats were observed in 33% and 40% of embryoid bodies treated with sotalol and quinidine, respectively, compared with negligible early afterdepolarizations and ectopic beats in untreated controls.Conclusions-We found that drug-induced arrhythmias can be recapitulated in hiPSC-CMs and documented with low impedance MEA. Our data indicate that the MEA/hiPSC-CM assay is a sensitive, robust, and efficient platform for testing drug effectiveness and for arrhythmia screening. This system may hold great potential for reducing drug development costs and may provide significant advantages over current industry standard assays that use immortalized cell lines or animal models.

Embryonic Stem Cells As a Novel Cell Source of Cell-Based Biosensors

Embryonic Stem Cells Biosensor and Its Application in Drug Analysis and Toxin Detection

In Vitro Assessing the Risk of Drug-Induced Cardiotoxicity by Embryonic Stem Cell-Based Biosensor

Beating Cardiac Cell-Based Biosensor and Its Application in Drugs Screening

Integrated Cell-Based Biosensor for Extracellular Electrophysiological Monitoring

Cardiac Cell-based Biosensor and Its Biomedical Applications

The Single-Cell Biosensor For Monitoring Extracellular Action Potential And Evaluating Drugs

Embryonic stem cell application in drug discovery

Cell-based biosensors based on light-addressable potentiometric sensors for single cell monitoring.

Cell-Based Biosensors and Bio-MEMS for Its New Applications

Cell-Based Biosensors for Single Cell Monitoring and Drug Analysis

3D Cell-Based Biosensor for Cell Viability and Drug Assessment by 3D Electric Cell/matrigel-Substrate Impedance Sensing.

Three-dimensional cardiomyocyte-based biosensor with tissue engineering scaffold

Screening Drug-Induced Arrhythmia Using Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes and Low-Impedance Microelectrode Arrays

Human-Induced Pluripotent Stem Cell-Based Differentiation of Cardiomyocyte Subtypes for Drug Discovery and Cell Therapy

Multifunctional Cardiomyocyte-Based Biosensor For Electrophysiology-Mechanical Beating-Growth Viability Monitoring

Drug evaluations using a novel microphysiometer based on cell-based biosensors

Current-Controlled Electrical Point-Source Stimulation of Embryonic Stem Cells

Small Molecules That Induce Cardiomyogenesis in Embryonic Stem Cells

Heart rhythm in vitro: measuring stem cell-derived pacemaker cells on microelectrode arrays

Synchronized High-Content Recording of Cardiomyocytes in Vitro by Integrated Cell-Based Biosensor